TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time.

Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation.

Due to limited capacity, in-person attendance is by invitation only. Analysts and institutional investors will be invited to pre-register and attend through an invite that will is distributed separately.

For questions regarding the event, please contact Teva's Investor Relations team at .

A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: .

An archived version of the webcast will be available within 24 hours after the end of the live discussion.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and "Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.



EN
07/05/2025

Underlying

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

Si Yong Ng
  • Si Yong Ng

Teva - Earnings Flash - Q2 FY 2025 Results - Lucror Analytics

Teva has reported good Q2/25 numbers, with adjusted EBITDA rising y-o-y. While reported sales were broadly flat, they would have increased if adjusting for the disposal of the Japan business venture (BV). Cash generation improved. Reported net leverage was broadly flat q-o-q, while liquidity remained adequate. We anticipate decent H2/25 results, with continued top-line-supported growth in Austedo, Ajovy and Uzedy to offset headwinds from the Japan BV disposal. Profitability should benefit fr...

Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL, Teva

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Trivium, Applus, Altice France (SFR), Casino Guichard-Perrachon, International Personal Finance, TeamSystem, Aston Martin, Virgin Media O2, Liberty Global, TalkTalk, Recordati, Tata Motors, Nexans, Italmatch Chemicals, Itelyum Group, Teva

 PRESS RELEASE

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth i...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continu...

Felix Fischer ... (+2)
  • Felix Fischer
  • Si Yong Ng

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva, AMS Osram

ResearchPool Subscriptions

Get the most out of your insights

Get in touch